AYTU BIOPHARMA, INC Fair Value Adjustment of Warrants
AYTU BIOPHARMA, INC (AYTU) reported Fair Value Adjustment of Warrants of -$3.50 million for the 3-month period ending 2025-09-30, per its 10-Q filed 2025-11-13.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:FairValueAdjustmentOfWarrants · last filed 2026-05-13
- AYTU BIOPHARMA, INC fair value adjustment of warrants for the quarter ending 2025-09-30 was -$3.50M.
- AYTU BIOPHARMA, INC fair value adjustment of warrants for the quarter ending 2025-03-31 was $2.30M.
- AYTU BIOPHARMA, INC fair value adjustment of warrants for the quarter ending 2024-12-31 was $3.00M.
- AYTU BIOPHARMA, INC fair value adjustment of warrants for the quarter ending 2024-09-30 was -$2.90M.
- AYTU BIOPHARMA, INC fair value adjustment of warrants for fiscal 2022 was -$211.00K.
- AYTU BIOPHARMA, INC fair value adjustment of warrants for fiscal 2021 was $0.00.
- AYTU BIOPHARMA, INC fair value adjustment of warrants for fiscal 2018 was $183.92K, a 12104.38% increase from fiscal 2017.
- AYTU BIOPHARMA, INC fair value adjustment of warrants for fiscal 2017 was $1.51K.
| Period end | Fair Value Adjustment of Warrants 1 month | Fair Value Adjustment of Warrants 3 month | Fair Value Adjustment of Warrants 6 month | Fair Value Adjustment of Warrants 9 month | Fair Value Adjustment of Warrants 12 month |
|---|---|---|---|---|---|
| 2025-09-30 | -$3.50M 10-Q · filed 2025-11-13 | ||||
| 2025-03-31 | $2.30M 10-Q · filed 2026-05-13 | $5.30M derived: sum of 2 quarters · filed 2026-05-13 | $8.20M 10-Q · filed 2026-05-13 | ||
| 2024-12-31 | $3.00M 10-Q · filed 2026-02-03 | $5.90M 10-Q · filed 2026-02-03 | |||
| 2024-09-30 | -$2.90M 10-Q · filed 2025-11-13 | ||||
| 2022-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-09-27 | -$211.00K derived: sum of 2 quarters · filed 2022-09-27 | -$211.00K 10-K · filed 2022-09-27 | ||
| 2022-03-31 | -$211.00K 10-Q · filed 2022-05-16 | -$211.00K 10-Q · filed 2022-05-16 | |||
| 2021-06-30 | $0.00 10-K · filed 2022-09-27 | ||||
| 2018-06-30 | $4.63K derived: 10-K 12 month − 10-Q 9 month · filed 2018-09-06 | $183.92K 10-K · filed 2018-09-06 | |||
| 2018-03-31 | $179.29K 10-Q · filed 2018-05-14 | ||||
| 2017-06-30 | $1.51K 10-K · filed 2018-09-06 | ||||
| 2017-02-28 | $23.00K 10-K · filed 2017-08-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |